Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.76
- Piotroski Score 4.00
- Grade Buy
- Symbol (NVAX)
- Company Novavax, Inc.
- Price $8.47
- Changes Percentage (5.29%)
- Change $0.43
- Day Low $8.00
- Day High $8.62
- Year High $23.86
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $22.00
- High Stock Price Target $174.00
- Low Stock Price Target $14.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.05
- Trailing P/E Ratio -5.96
- Forward P/E Ratio -5.96
- P/E Growth -5.96
- Net Income $-545,062,000
Income Statement
Quarterly
Annual
Latest News of NVAX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Novavax, Inc. (NVAX) the Best High-Flying Stock to Buy?
A list of top high-flying stocks includes Novavax, Inc. (NASDAQ:NVAX) and insights on market trends. Novavax's focus on cost efficiency, strategic partnerships, and promising financial outlook are hig...
By Yahoo! Finance | 1 month ago -
Novavax (NVAX): Analysts Are Bullish On This Under The Radar Stock Now
A list of 7 Best Under The Radar Stocks to Buy According to Analysts includes Novavax (NASDAQ:NVAX). Billionaire Mark Cuban highlights the importance of addressing national debt, deficits, and the imp...
By Yahoo! Finance | 1 month ago -
Loss-Making Novavax, Inc. (NASDAQ:NVAX) Set To Breakeven
Novavax, Inc. is nearing breakeven according to industry analysts, expecting profitability in 2024 after a final loss in 2023. With a projected 70% yearly growth rate, the company's path to profitabil...
By Yahoo! Finance | 3 months ago
